Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
San Francisco–based Aeovian Pharmaceuticals has raised $37 million in series A financing to develop a small-molecule drug candidate that inhibits a protein complex called mammalian target of rapamycin complex 1 (mTORC1). Existing mTORC1 inhibitors also target a similar complex, called mTORC2, causing several immune and metabolic side effects. Aeovian’s first program will inhibit mTORC1 to treat a nervous system disease, but the firm later plans antiaging studies.
This article has been sent to the following recipient: